Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


E. O. Zhuravleva has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacovigilance in the Geriatric Population: Analysis of Risk Management Plans for Medicinal Products in Russia in 2024

    by N. V. Tereshkina, N. Yu. Velts, E. O. Zhuravleva, G. V. Kutekhova, S. V. Glagolev, V. V. Kosenko, Н. Ю. Вельц

    INTRODUCTION. Geriatric patients are the fastest growing demographic group, accounting for over half of all medicinal product users. Pharmacovigilance in this population is influenced by age-related physiological changes and social factors. Risk management plans (RMPs), developed by marketing authorisation holders, play a preventive role in managing the risks associated with the use of medicinal products in elderly patients.AIM. This study aimed to evaluate the completeness of information on the geriatric group within target populations in RMPs for medicinal products launched in the Russian pharmaceutical market in 2024.MATERIALS AND METHODS. This study analysed 110 RMPs for medicinal products potentially applicable to geriatric populations, submitted to the Scientific Centre for Expert Evaluation of Medicinal Products between January and December 2024. All the documents included full modules and sections.RESULTS. The analysis revealed critical gaps in RMPs data for geriatric populations, including the epidemiology of indication(s) and target population(s) (these data were missing in 52.0% of cases); clinical trial exposure (patients over 60 years were excluded from clinical trials in 47.3% of cases); populations not studied in clinical trials (these data were unreported in 63.6% of cases); post-authorisation experience in elderly or senile patients (these data were missing in 83.6% of cases); and potential harm from overdose (risk warnings were absent in 96.4% of cases). There were no additional risk minimisation measures for emphasising the considerations for medicinal product use in the geriatric population in the analysed documents.CONCLUSIONS. When drafting RMPs, marketing authorisation holders and medicinal product developers do not pay sufficient attention to geriatric populations and often underestimate the risks associated with medicinal product use in elderly and senile patients. The issues associated with the use of medicinal products in geriatric patients can be mitigated through rigorous risk management practices applied during pharmacotherapy. The parties concerned should consider this when drafting the summary of medicinal product characteristics and the patient information leaflet, labelling the medicinal product, and selecting the package size.

  • Open Access

    Submission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Requirements and Typical Errors

    by N. Yu. Velts, E. O. Zhuravleva, G. V. Kutekhova, N. V. Tereshkina, Н. Ю. Вельц

    INTRODUCTION . Documents on the pharmacovigilance system of the marketing authorisation holder (MAH), including the Pharmacovigilance System Master File (PSMF) and the PSMF-based summary of the pharmacovigilance system (SPS), are a mandatory component of the registration dossier for a medicinal product. Applicants must submit and update these documents in strict accordance with the legislation of the Eurasian Economic Union (EAEU). Systematisation of the requirements for drafting and submitting documents on the pharmacovigilance system will help applicants streamline the documentation process. AIM . This study aimed to analyse the requirements for submitting either the PSMF or the SPS, depending on the EAEU marketing authorisation procedure, and to describe typical errors made by applicants when submitting these documents. DISCUSSION . The content of dossier documents on the pharmacovigilance system is regulated by the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union (Decision No. 87 of the Council of the Eurasian Economic Commission (EEC) dated 3 November 2016), and their submission is governed by the Rules of Marketing Authorisation and Assessment of Medicinal Products for Human Use (EEC Council Decision No. 78 dated 3 November 2016). MAHs are required to keep documents on the pharmacovigilance system and the corresponding registration dossiers up to date. This article summarises the specific requirements for submitting either the PSMF or the SPS, depending on the EAEU marketing authorisation procedure. Additionally, this article highlights typical errors made by MAHs when preparing documents on the pharmacovigilance system. According to the EAEU Rules of Good Pharmacovigilance Practice, the first application submitted for marketing authorisation of a medicinal product in the EAEU should include the PSMF, and subsequent applications should include the SPS as part of the registration dossier. Changes to the pharmacovigilance documents should be made in accordance with the classifier (EEC Council Decision No. 78 dated 3 November 2016). CONCLUSIONS . This analysis of the requirements for the PSMF or the SPS as part of various marketing authorisation procedures will facilitate compliance with the requirements of the EAEU legislative acts and ensure correct submission of necessary documents on the pharmacovigilance system by applicants. In addition, regulatory authorities will make fewer requests to submit missing information and grant more marketing authorisations. ERRATUM Erratum: Velts N.Yu. et al. Submission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Requirements and Typical Errors https://www.risksafety.ru/jour/article/view/476

  • Open Access

    Pharmacovigilance System Master File: An Overview of Changes in the EAEU Good Pharmacovigilance Practice

    by N. Yu. Velts, E. O. Zhuravleva, G. V. Kutekhova, N. V. Tereshkina, Н. Ю. Вельц

    Мастер-файл системы фармаконадзора: обзор изменений в Правилах надлежащей практики фармаконадзора ЕАЭС


  • Open Access

    Analysis of the Causes for Renal Dysfunction during Antibiotic Therapy in a Patient with Lyme Disease

    by N. Yu. Velts, E. O. Zhuravleva, G. V. Kutekhova, N. V. Tereshkina, A. O. Lovkova, K. V. Gorelov, V. A. Polivanov, S. M. Gyulakhmedova, Н. Ю. Вельц

    Adverse drug reactions (ADRs) are recorded throughout the lifecycle of a medicinal product. In the post-marketing period, new ADRs are primarily identified via drug safety signals. In order to assess a signal and establish causality between an adverse drug reaction and a suspected medicinal product, it is necessary to evaluate the signal strength and quality.The aim of the study was to analyse the information submitted to Russian regulatory authorities by a patient and check it for a potential causal association of acute tubulointerstitial nephritis (ATIN) with the use of ceftriaxone and with the patient’s principal diagnosis, Lyme disease.Materials and methods: the authors analysed the patient’s submission received by the Ministry of Health of the Russian Federation in 2022 with a complaint that the treatment of Lyme disease with ceftriaxone had caused ATIN. The probability of a causal relationship between the medicinal product and the ADR was evaluated using the Naranjo algorithm.Results: according to the review of literature and the spontaneous reports collected in Pharmacovigilance 2.0, the database in the Automated Information System of the Russian Federal Service for Surveillance in Healthcare, both ceftriaxone and the underlying condition (Lyme disease) may cause renal abnormalities. Ceftriaxone is potentially nephrotoxic; it mainly affects the tubular system of the kidneys. Borreliosis may cause kidney damage as well; such damage manifests clinically as rapidly progressing and fatal damage to the glomeruli.Conclusions: the probability of a causal relationship between the development of ATIN in the complainant and the use of ceftriaxone was categorised as “possible”. However, the information available did not allow for establishing a definite relationship between kidney damage and the use of the medicinal product. Further monitoring of similar cases is necessary to minimise the risks of developing this pathology during treatment with ceftriaxone.


  • Open Access

    Safety of Antibacterial and Antiprotozoal Medicinal Products

    by E. V. Shubnikova, T. M. Bukatina, A. A. Druzhinina, E. O. Zhuravleva, G. V. Kutekhova, N. Yu. Velts, Н. Ю. Вельц

    The experts of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recalls of antibacterial and antiprotozoal medicinal products and/or the need for labelling updates due to changes in the safety profile. The analysis revealed 16 decisions containing information on the following medicines registered in Russia: ertapenem, сeftriaxone, cefazolin, аmoxicillin, сefoperazone+sulbactam, piperacillin+tazobactam, сlindamycin, teicoplanin, rifampin, co-trimoxazole, hydroxychloroquine.


  • Open Access

    Analysis of Noncompliances with Legislative Requirements in Pharmacovigilance Materials of Registration Dossiers

    by E. O. Zhuravleva, N. Yu. Velts, G. V. Kutekhova, Н. Ю. Вельц

    Since 1 January 2021 the authorisation of medicines in the Russian Federation has to be performed according to the Eurasian Economic Union (EAEU) procedure. The Pharmacovigilance System Master File (PSMF) is the main document describing the pharmacovigilance system of the marketing authorisation holder (MAH) or its authorised representative. The aim of the study was to analyse noncompliances with the EAEU requirements, which were revealed during PSMF assessment.Materials and methods: the authors analysed 687 pharmacovigilance documents included in registration dossiers that were submitted for assessment from 1 January to 30 June, 2021. Results: the authors identified and systematised the main noncompliances with the EAEU requirements in terms of presentation, content, completeness of each PSMF section. They analysed the frequency of noncompliances in PSMFs and identified the most frequent flaws of MAHs’ pharmacovigilance systems.Conclusions: the authors give recommendations for elimination of significant noncompliances identified during PSMF assessment, which may include: timely updating, maintenance, and revision of the documents in accordance with changes in legislation and any other significant changes, regular training of pharmacovigilance staff, etc. The results of this review will be useful for MAHs as the main participants of the marketing authorisation process who are directly involved in the pharmacovigilance system management at the pre- and post-authorisation stages, and will help them prevent potential mistakes when drawing up pharmacovigilance system documents.


  • Open Access

    Drug Safety Monitoring Information

    by E. V. Shubnikova, E. O. Zhuravleva, N. Yu. Velts, P. M. Giulakhmedova, A. A. Druzhinina, Н. Ю. Вельц

    Analysis of administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre for Expert Evaluation of Medicinal Products revealed 19 administrative decisions. These decisions contained information on the following medicines registered in Russia: amikacin, tobramycin, gentamicin, neomycin, ciprofloxacin, delafloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, сeftriaxone, ceftaroline, rifapentine, tigecycline, bacitracin, ertapenem, daptomycin, erythromycin, fosfomycin, ampicillin+sulbactam, chloroquine, hydroxychloroquine.


  • Open Access

    Expert Evaluation of Pharmacovigilance System Documents Included in the Registration Dossier

    by I. I. Snegireva, E. O. Zhuravleva, N. Yu. Velts, Н. Ю. Вельц

    The Russian Federation and the member states of the Eurasian Economic Union (EAEU) are working on the creation of a common pharmaceutical market. EAEU marketing authorisation may be granted to those pharmaceutical companies whose activities comply with the Good Pharmacovigilance Practice (GVP). The aim of the study was to analyse pharmacovigilance system documents submitted as part of registration dossiers of medicines and to identify problems that may arise during preparation of the pharmacovigilance system master file (PSMF). The authors analysed the PSMF, which makes part of the registration dossier, for compliance with the EAEU GVP requirements for submission, content, and completeness of all sections of the document. They identified the most common types of errors in PSMF preparation and analysed conditions when a PSMF is required or, alternatively, when a brief summary of the pharmacovigilance system of the marketing authorisation holder will suffice. The paper summarises specific aspects of incorporating pharmacovigilance system documents in regulatory submissions, as well as aspects of presenting pharmacovigilance system data when bringing the registration dossier in line with the EAEU requirements. This information may be useful for marketing authorisation holders who are the main stakeholders in the medicine authorisation process and who are directly involved in the pharmacovigilance system management during the authorisation and post-authorisation stages of the drug life-cycle.


  • Фармакогенетические тесты антипсихотик-индуцированного повышения массы тела

    by Евгения О. Журавлева, Н. Ю. Вельц, И. И. Снегирева, Г. В. Кутехова, Р. Н. Аляутдин

    Антипсихотические препараты второго поколения, по сравнению с антипсихотическими препаратами первого поколения, наиболее эффективны в отношении психотических симптомов и значительно в меньшей степени способны развивать экстрапирамидные нарушения, такие как паркинсонизм и поздняя дискинезия. Однако их прием в значительной степени ассоциирован с существенным повышением массы тела у пациентов. Проанализированы достижения, достигнутые в поле фармакогенетики антипсихотик-индуцированного увеличения массы тела.

  • Open Access

    Nanoscale Therapeutic System: Safety Assessment Features

    by E. M. Bovina, B. K. Romanov, A. S. Kazakov, N. Yu. Velts, E. O. Zhuravleva, T. M. Bukatina, R. N. Alyautdin, V. A. Merkulov, Н. Ю. Вельц

    Nanoscale drugs differ in special physicochemical, biological, pharmacokinetic parameters. These properties can be used to provide targeted delivery, prolong the action of drugs, as well as reduce their side effects. An important problem that needs attention is the study of the potential risks arising from the treatment of such drugs. The aim of the study: analysis of the requirements of domestic and foreign regulators for the safety of nanoscale drugs. The paper presents the classification of the most promising nanosystems containing drugs, and an analysis of the existing principles for assessing their safety in Russia and abroad has been carried out. It was shown that when assessing the safety of nano-sized drugs, along with the properties of the active substance, it is necessary to take into account the properties of the nanosystem (polymer coating, carrier, etc.), related to its size, distribution pattern, charge of nanoparticles, and ability to induce oxidative stress. Domestic and foreign regulatory documents governing the procedure for assessing the safety of pharmacological substances derived from nanotechnology was analyzed. Conclusions: Despite the availability of recommendations from regulatory authorities, further improvement of the requirements for registration and safety assessment of nanoscale drugs is necessary. Further development of the regulatory framework governing the development, quality, efficiency and safety of nanomaterials in medicine is necessary, taking into account the structural issues of the active substance and nano-carriers.